Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6261-6271

  Wistuba, Ignacio I ^a   Behrens, Carmen ^a   Lombardi, Francesca ^c   Wagner, Susanne ^b   Fujimoto, Junya ^a   Raso, M Gabriela ^a   Spaggiari, Lorenzo ^c   Galetta, Domenico ^c   Riley, Robyn ^b   Hughes, Elisha ^b   Reid, Julia ^b   Sangale, Zaina ^b   Swisher, Steven G ^a   Kalhor, Neda ^a   Moran, Cesar A ^a   Gutin, Alexander ^b   Lanchbury, Jerry S ^b   Barberis, Massimo ^c   Kim, Edward S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Myriad Genetic Laboratories   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL CYCLE PROGRESSION GENE SCORE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DNA MICROARRAY; EARLY CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL PREDICTION; VALIDATION STUDY;

ADENOCARCINOMA; AGED; CELL CYCLE; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84888087538     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0596     Document Type: Article

References (35)

1. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small cell lung cancer guideline. J Clin Oncol 2007;25:5506-18. (Pubitemid 350232227)
2. Crino L, Weder W, van Meerbeeck J, Felip E, ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v103-15.
3. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
4. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
5. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007;13:73-7.
6. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801.
7. Li Z, Liu H, Li L. Video-assisted thoracoscopic surgery versus open lobectomy for stage I lung cancer: a meta-analysis of long-term outcomes. Exp Therapeutic Med 2012;3:886-92.
8. Cajipe MD, Chu D, Bakaeen FG, Casal RF, Le Maire SA, Coselli JS, al. Video-assisted thoracoscopic lobectomy is associated with better perioperative outcomes than open lobectomy in a veteran population. Am J Surg 2012;204:607-12.
9. Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg 2010;139:976-81.
10. The National Lung Screening Trial Research Team. Reduced lungcancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
11. Matsubura D, Morikawa T, Goto A, Nakajima J, Fukayama M, Niki T. Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis. Mod Path 2009;22:776-85.
12. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2010;17:1490-501.
13. Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17:668-75. (Pubitemid 29075256)
14. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102:464-74.
15. Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 2009;10:151-7.
16. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, non-small cell lung cancer: development and international validation studies. Lancet 2012;379:823-32.
17. Kratz JR, Van Den Eeden SK, He J, Jablons DM, Mann MJ. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 2012;308:1629-31.
18. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006;8:216-27.
19. Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genom 2008;1:11-25.
20. Starmans M H W, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, et al. Robust prognostic value of a knowledgebased proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008;99:1884-90.
21. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65-76.
22. Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 1993;128:1382-90. (Pubitemid 23360034)
23. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006;106:1595-601.
24. Corson TW, Zhu QC, Lau SK, Shepherd FA, Tsao MS, Gallie BL. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 2007;13:3229-34. (Pubitemid 46944906)
25. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, et al. BRCA1: a novel prognostic factor in resectable non-small-cell lung cancer. PLoS One 2007;2:e1129.
26. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
27. Park YY, Park ES, Kim SB, Kim SC, Sohn BH, Chu IS, et al. Development and validation of a prognostic gene-expression signature in lung adenocarcinoma. PLoS One 2012;7:e44225.
28. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9.
29. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes for recurrence and death from prostate cancer: a retrospective study in two cohorts. Lancet Oncol 2011;12:245-55.
30. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinoma. Cancer Res 2012;72:100-11.
31. Zhang MJ, Klein JP. Confidence bands for the difference of two survival curves under the proportional hazards model. Lifetime Data Anal 2001;7:243-54. (Pubitemid 33692880)
32. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
33. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92. (Pubitemid 44390989)
34. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary nonsmall cell lung carcinoma. Clin Cancer Res 2005;11:232-41. (Pubitemid 40075800)
35. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2010/, based on November2012SEER data submission, posted to the SEER web site, April 2013.